

TScan Therapeutics announces collaboration and licensing deal with Novartis

Client News

April 15, 2020

Gunderson Dettmer client TScan Therapeutics, an immunotherapy company for blood cancers, announced it had entered into a licensing and collaboration agreement with Novartis.

In [a story about the agreement](#) TScan Chief Scientific Officer Gavin MacBeath, Ph.D., said “When we discover a new target, we simultaneously discover the TCR that recognizes that target, so we lump target discovery and therapeutic discovery into one process.” With each hit, the company immediately has leads that can be pushed toward the clinic—“an aspect that really captured Novartis’ attention.”

The Gunderson deal team was led by partner Brendan McCarthy and included Tim Ehrlich and Brittany Nicely.

Related People



Brendan C. McCarthy

PARTNER

P +1 858 436 8013



Timothy H. Ehrlich

PARTNER

P +1 617 648 9399



Brittany M. Nicely

ASSOCIATE

P +1 858 436 8067

Featured Insights

CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific

Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act